Skip to main content
. Author manuscript; available in PMC: 2017 Jun 15.
Published in final edited form as: Cancer. 2016 Apr 8;122(12):1928–1936. doi: 10.1002/cncr.29987

Figure 3.

Figure 3

The amount of residual tumor as a prognostic factor in NF1 (Fig. 3A) or non-NF1 (Fig. 3B) patients. The EFS outcomes for these 3 groups were significantly different for NF1 patients (Fig. 3A, P=0.02, log-rank trend test P=0.01), but not for non-NF1 patients (Fig. 3B, P=0.18).